UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
------------------------
Date of Report (Date of earliest event reported): July 31, 2003
IMPAX LABORATORIES, INC.
----------------------------------------------------------------
(Exact name of Registrant as specified in its charter)
Delaware 0-27354 65-0403311
- ------------------------------- ----------------------- ------------------
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer
incorporation Identification No.)
30381 Huntwood Avenue
Hayward, CA 94544
------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: (510) 476-2000
--------------
Item 5. Other Events and Regulation FD Disclosure.
On July 31, 2003, the Company issued a press release announcing that it
entered into an agreement with subsidiaries of Andrx Corporation and Teva
Pharmaceutical Industries Ltd. A copy of that press release is attached hereto
as Exhibit 99.1 and is incorporated herein by reference.
Item 7. Financial Statements and Exhibits.
Financial Statements:
Not applicable
Exhibits:
99.1 Press release dated July 31, 2003 announcing the agreement with
subsidiaries of Andrx Corporation and Teva Pharmaceutical Industries Ltd.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Impax Laboratories, Inc.
Date: July 31, 2003 By: /s/ Cornel C. Spiegler
--------------------------
Cornel C. Spiegler
Chief Financial Officer